# A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

> **NCT05296798** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 922 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Phesgo
- **DRUG:** Giredestrant
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** LHRH Agonist
- **DRUG:** Optional Endocrine Therapy of Investigator's Choice

## Key facts

- **NCT ID:** NCT05296798
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-18
- **Primary completion:** 2027-10-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 922 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05296798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05296798, "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05296798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*